FGF23 and chronic kidney disease: In chronic kidney disease (CKD), the hyperphosphaturic osteocyte-derived hormone FGF-23 increases to compensate for phosphate retention and further inhibits renal 1α-hydroxylase expression, and induces the expression of 24-hydroxylase responsible for the degradation of 1,25-(OH2)D.